Vita Life SciencesASX:VLS 87 5-Year Yield-on-Cost % is 15.32 as of Jul. 01, 2026, which is 45% above its 10-year median of 10.59. GuruFocus rates ASX:VLS with a GF Score™ of 87/100 and a GF Value™ of A$2.48 (Fairly Valued). The stock has 1 warning sign investors should review. Among 516 Drug Manufacturers companies, Vita Life Sciences ranks better than 93.8% on this metric.
Vita Life Sciences's yield on cost for the quarter that ended in Dec. 2025 was 15.32.
The historical rank and industry rank for Vita Life Sciences's 5-Year Yield-on-Cost % or its related term are showing as below:
ASX:VLS'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 5.39 Med: 10.59 Max: 19.26
Current: 15.32
During the past 13 years, Vita Life Sciences's highest Yield on Cost was 19.26. The lowest was 5.39. And the median was 10.59.
ASX:VLS's 5-Year Yield-on-Cost % is ranked better than 93.8% of 516
companies
in the Drug Manufacturers industry
Industry Median: 2.35
vs ASX:VLS: 15.32
Vita Life Sciences (ASX:VLS) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Vita Life Sciences 5-Year Yield-on-Cost % Related Terms
ASX:VLS vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's 5-Year Yield-on-Cost % falls into.
Vita Life Sciences 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Vita Life Sciences (ASX:VLS) has a 5-Year Yield-on-Cost % of 15.32 as of Jul. 01, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Vita Life Sciences and its competitors. This is 45% above median its historical median of 10.59. Over the past decade, Vita Life Sciences' 5-Year Yield-on-Cost % has ranged from 5.39 to 19.26. According to the industry distribution chart, Vita Life Sciences ranks #32 out of 516 companies in the Drug Manufacturers industry, placing it in the top 6.2%.
Is Vita Life Sciences' 5-Year Yield-on-Cost % too high?
Vita Life Sciences' current 5-Year Yield-on-Cost % of 15.32 is 45% above median its 10-year median of 10.59. Over the past 10 years, this metric has ranged from a low of 5.39 to a high of 19.26. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.35. Vita Life Sciences' value of 15.32 is 551.9% above this industry median. Based on the distribution chart, Vita Life Sciences ranks #32 out of 516 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vita Life Sciences has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #32 out of 516 companies for 5-Year Yield-on-Cost %. This places Vita Life Sciences in the top 6% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.35. Vita Life Sciences' value of 15.32 is 551.9% above this benchmark. Historically, Vita Life Sciences' own 5-Year Yield-on-Cost % has ranged from 5.39 to 19.26 over the past decade. While the company's 10-year median is 10.59 vs. the industry median of 2.35, Vita Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.35, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current 5-Year Yield-on-Cost % of 15.32 is 551.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current 5-Year Yield-on-Cost % is 15.32, which is 45% above median its own 10-year median of 10.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.48, compared to a current price of A$2.50 — trading 0.8% above its estimated fair value. The current 5-Year Yield-on-Cost % is 15.32, which is 45% above median its 10-year median of 10.59 and 551.9% above the Drug Manufacturers industry median of 2.35. Vita Life Sciences' overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current 5-Year Yield-on-Cost % is 15.32 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued.
The current stock price of A$2.50 is trading 0.8% above its estimated GF Value™ of A$2.48.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
5-Year Yield-on-Cost %: 15.32 (45% above median its 10-year median of 10.59)
GF Value™: A$2.48 vs. price of A$2.50 (0.8% above fair value)
Industry Position: 551.9% above the Drug Manufacturers median (#32 of 516)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
87GF Score
Get the complete analysis for ASX:VLS
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 